Skip to main content

Table 5 Glaucoma Symptom Scale (GSS) scores at baseline and week 12 by diagnosis and gender, mean ± SD (ITT population)

From: Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination

  

Diagnosis

 

All

N = 383

OAG

N = 208

OHT

N = 161

Both

N = 14

Global GSS score

    

   Baseline

86.15 ± 15.73

84.99 ± 15.89

87.29 ± 15.54

89.41 ± 15.67

   Week 12

88.49 ± 14.32

86.81 ± 15.91

90.19 ± 12.50

91.59 ± 8.50

Non-visual GSS score

    

   Baseline

84.60 ± 17.09

84.70 ± 16.14

84.34 ± 18.04

86.11 ± 20.52

   Week 12

86.78 ± 15.40

84.74 ± 17.05

89.08 ± 12.95

88.10 ± 14.88

Visual GSS score

    

   Baseline

87.76 ± 18.46

85.97 ± 19.95

89.54 ± 16.81

92.79 ± 11.08

   Week 12

89.76 ± 17.26

88.33 ± 19.18

91.06 ± 15.19

94.64 ± 7.70

 

Gender

 
 

Male

N = 179

 

Female

N = 204

 

Global GSS score

    

   Baseline

87.28 ± 15.24

 

85.19 ± 16.13

 

   Week 12

90.05 ± 13.96

 

87.08 ± 14.55

 

Non-visual GSS score

    

   Baseline

86.52 ± 15.77

 

82.95 ± 18.02

 

   Week 12

88.81 ± 14.17

 

84.90 ± 16.27

 

Visual GSS score

    

   Baseline

88.15 ± 18.29

 

87.43 ± 18.64

 

   Week 12

90.81 ± 16.40

 

88.83 ± 17.98

 
  1. Both = OAG and OHT; ITT = intent-to-treat population; OAG = open-angle glaucoma;
  2. OHT = ocular hypertension; SD = standard deviation.
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us